Skip to main content
Premium Trial:

Request an Annual Quote

Open Peer Review Is One Thing, But This Is Ridiculous

Well, Pfizer, we hope you really, really needed those names. For some time now the pharma's been in the news for trying to get several journals to open up their confidential peer-review records for use in the company's legal defense of its drugs, Celebrex and Bextra. Now that it looks like Pfizer will be denied all of these requests by the courts -- check out this blog post from Derek Lowe for more -- bloggers are happily taking the opportunity to scold the pharma and remind us of the benefits of peer review.

Over at the Periodic Tabloid, Tom Tritton says this is a case of two values colliding: the need for peer review and the desire to innovate. Tritton says the need for "independent, confidential scientific review" is of greater public interest and therefore should win out over a company trying to defend the drugs it brought to market. "No more legal maneuverings on peer review please, Pfizer," he writes.

 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.